

A 2024

16

PARIS
HEPATOLOGY
CONFERENCE

Hybrid PHC 2024
Institut Pasteur - Paris
18 - 19 March

International Conference
on the Management of
Liver Diseases

Organised by
Patrick Marcellin & Laurent Castera
Association for the Promotion
of Hepatologic Care (APHC)

PROGRAM

www.aphc.info

Production
& Logistics

live!

08:00 **Registration and Welcome coffee**
08:30 Visit of the exhibition and posters area

08:30 **Introduction**
Patrick MARCELLIN (France), Laurent CASTERA (France)

08:40 **HEPATITIS B - OPTIMAL MANAGEMENT**
10:00 Chairs: Rafael ESTEBAN (Spain), Jidong JIA (China)

08:40 **Long term efficacy and safety of NUCs: follow-up studies of TDF and TAF**
Maria BUTI (Spain)

08:55 **Effects of NUC therapy on the incidence of HCC**
Seng Gee LIM (Singapore)

09:10 **Controversy: treat everyone with detectable HBV DNA?**
Yes ~ Jidong JIA (China)
No ~ Thomas BERG (Germany)
Discussion

09:40 **New antivirals and new therapeutic strategies**
Fabien ZOULIM (France)

10:00 **Coffee break**
10:30 Visit of the exhibition and posters area

10:30 **STATE OF THE ART LECTURE**
10:50 **Advances in the management of alcohol-related liver disease**
Aleksander KRAG (Denmark)

10:50 **HEPATITIS DELTA - OPTIMAL TREATMENT**
12:10 Chairs: Mario RIZZETTO (Italy), Kosh AGARWAL (UK)

10:50 **The EASL guidelines on hepatitis delta**
Tarik ASSELAH (France)

11:05 **Is chronic hepatitis delta more severe than chronic hepatitis B?**
Raymundo PARANA (Brazil)

11:20 **PEG-IFN monotherapy**
Georgios PAPTAEODORIDIS (Greece)

11:35 **Do NUCs improve the efficacy of Bulevirtide?**
Vasily ISAKOV (Russia)

11:50 **Controversy: bulevirtide - Combine or not to PEG IFN?**
Yes ~ Heiner WEDEMEYER (Germany)
No ~ Pietro LAMPERTICO (Italy)
Discussion

12:10 **STATE OF THE ART LECTURE**
12:30 **What's new in auto-immune liver diseases?**

Michael MANN (Germany)

12:30 **Break**
12:45 Lunch boxes distribution in the exhibition

12:45 **SYMPOSIUM** ~ CIS Auditorium Partners' sessions program
13:45 **& WORKSHOP** ~ Congress center, Room 1

13:45 **Coffee break**
14:00 Visit of the exhibition and posters area

14:00 **R&D SESSION 1** Partners' sessions program
14:45 **The drug pipelines presented by Companies**

14:45 **HEPATITIS C: ARE WE ON TIME?**
15:40 Chairs: Robert FLISIAK (Poland), Ana Carolina FERREIRA NETTO CARDOSO (Brazil)

14:45 **What actions to take to achieve HCV elimination?**
Robert GISH (USA)

15:00 **Improving HCV-related morbidity and mortality**
Robert FLISIAK (Poland)

15:15 **Improving immune-related extrahepatic manifestations**
Patrice CACOUB (France)

15:30 **Discussion**

15:40 **Coffee break**
16:10 Visit of the exhibition and posters area

16:10 **ADVANCES IN THE MANAGEMENT OF END-STAGE LIVER DISEASE**
17:20 Chairs: Shiv SARIN (India), Richard MOREAU (France)

16:10 **ICU admission of patients with cirrhosis: indications, futility**
Francois DURAND (France)

16:25 **New insights into decompensated cirrhosis: the ACLARA study**
Adrian GADANO (Argentina)

16:40 **Encephalopathy revisited**
Dominique THABUT (France)

16:55 **Sarcopenia, frailty in end-stage liver disease**
Claire FRANCOZ (France)

17:10 **Discussion**

17:20 **AWARD 2024**
17:50 Chair: Patrick MARCELLIN (France)

17:20 **Vascular liver diseases**
Dominique VALLA (France)

17:50 **POSTER PRIZE**
18:00 Chair: Patrick MARCELLIN (France)

18:00 TAKE HOME MESSAGES

18:20 Geoffrey DUSHEIKO (UK)

18:20 **Conclusion**

Patrick MARCELLIN (France), Laurent CASTERA (France)

18:30 **SYMPOSIUM** ~ CIS Auditorium

Partners' sessions program

19:00

19:00 End of the 1st day

08:00 **Registration and Welcome coffee**
08:30 Visit of the exhibition and posters area

08:30 **Introduction**
Patrick MARCELLIN (France), Laurent CASTERA (France)

08:40 **MASLD AND TYPE 2 DIABETES (T2D)**
09:40 Chairs: Jeffrey LAZARUS (Spain), Jörn SCHATTENBERG (Germany)

08:40 **Pathophysiological relationship between MASLD and T2D**
Amalia GASTALDELLI (Italy)

08:55 **High prevalence of severe liver lesions in T2D: lessons from QUID-NASH**
Laurent CASTERA (France)

09:10 **Impact of MASH on T2D treatment and management**
Michael RODEN (Germany)

09:25 **Discussion**

09:40 **STATE-OF-THE ART LECTURE**
10:00 **Update on the global epidemiology of MASLD and MASH**
Zobair YOUNOSSI (USA)

10:00 **Coffee break**
10:30 Visit of the exhibition and posters area

10:30 **NON-INVASIVE TESTS (NITS) IN MASLD IN 2024**
11:30 Chairs: Lawrence SERFATY (France), Massimo PINZANI (UK)

10:30 **Limitations and challenges in the use of NITs**
Emmanouil TSOCHATZIS (UK)

10:45 **Prognostic value of NITs**
Mazen NOUREDDIN (USA)

11:00 **NITs use in clinical practice**
Jérôme BOURSIER (France)

11:15 **Discussion**

11:30 **TREATING MASH IN 2024**
12:30 Chairs: Laurent CASTERA (France), Arun SANYAL (USA)

11:30 **Benefit of weight loss in MASH**
Raluca PAÍS (France)

11:45 **Clinical trial landscape in MASH**
Stephen HARRISON (USA)

12:00 **Treatment response in MASH: are we ready for NITs?**
Arun SANYAL (USA)

12:15 **Discussion**

12:30 **Break**
12:45 Lunch boxes distribution in the exhibition

12:45 **SYMPOSIUM** ~ CIS Auditorium Partners' sessions program
13:45 **& WORKSHOP** ~ Congress center, Room 1

13:45 **Coffee break**
14:00 Visit of the exhibition and posters area

14:00 **R&D SESSION 2** Partners' sessions program
14:45 **The drug pipelines presented by Companies**

14:45 **HCC SESSION 1: DIAGNOSIS AND STAGING**
15:40 Chairs: Massimo COLOMBO (Italy), Pierre NAHON (France)

14:45 **Risk stratification-based surveillance of HCC**
Peter JEPSSEN (Denmark)

15:00 **Toward multiscale imaging of HCC**
Valérie PARADIS, Maxime RONOT (France)

15:30 **Discussion**

15:40 **STATE OF THE ART LECTURE**
16:00 **Management of invasive procedures in patients with cirrhosis**
Pierre-Emmanuel RAUTOU (France)

16:00 **Coffee break**
16:30 Visit of the exhibition and posters area

16:30 **HCC SESSION 2: MANAGEMENT**
17:30 Chair: Norah TERRAULT (USA), Massimo COLOMBO (Italy)

16:30 **Interventional radiology**
Laura CROCETTI (Italy)

16:45 **Towards manipulation of responses to immunotherapy in HCC**
Josep M. LLOVET (Spain)

17:00 **Expanding liver transplantation options**
Norah TERRAULT (USA)

17:15 **Discussion**

17:30 **TAKE HOME MESSAGES**
17:50 Michael FRIED (USA)

17:50 **Conclusion**
Patrick MARCELLIN (France), Laurent CASTERA (France)

18:00 **End of the congress**

CIS Auditorium

12:45 **WORKSHOP ABBVIE**
13:45 **Unlocking the promise of artificial intelligence to achieve HCV elimination**

abbvie

Chair: Markus CORNBERG (Hannover, Germany)

12:45 **Introduction**
Markus CORNBERG (Hannover, Germany)

12:50 **Optimizing linkage to care in hospitals using AI**
Juan TURNES (Vigo, Spain)

13:10 **HCV Patient Activation through AI**
Mike BOYADJIAN (Chicago, USA)

13:20 **Q&A with audience**

Congress center, Room 1

12:45 **WORKSHOP ~ supported by an unrestricted grant from CYMABAY**
13:45 **Emerging therapies in the management of people living with PBC**

CYMABAY

Chairs: Gideon HIRSCHFIELD (Toronto, Canada), Stephen HARRISON (San Antonio, USA)

12:45 **PPARs: an emerging therapeutic option for people living with PBC**
Gideon HIRSCHFIELD (Toronto, Canada), Stephen HARRISON (San Antonio, USA)

12:50 **Redefining the treatment landscape in PBC: target potency, safety and normality**
Gideon HIRSCHFIELD (Toronto, Canada)

13:05 **Phase 3 Trials Primary and Key Secondary Endpoints: Composite endpoint, ALP normalization and itch**
Stephen HARRISON (San Antonio, USA)

13:25 **Q&A with audience**

14:00 **R&D SESSION 1:**
14:45 **The drug pipelines presented by Companies**

Chairs: Raymond SCHINAZI (USA), Geoffrey DUSHEIKO (UK)

14:00 **GILEAD**
Gilead Commitment to Liver Diseases
Christophe HEZODE (Medical Affairs, Gilead)

14:15 **BOSTON PHARMACEUTICALS**
BOS-580, a once-monthly FGF21 analogue, investigational treatment for MASH
Matthew BRYANT (VP of Medical Affairs, Boston Pharmaceuticals)

14:30 **GSK**
GSK Hepatology Pipeline
Diogo FERRINHO (Global Medical Affairs Lead, GSK)

18:30 **SYMPOSIUM GILEAD**
19:00 **Chronic viral hepatitis C & Delta**



Chair: Maria BUTI (Barcelona, Spain)

18:30 10 years of all-oral therapies for HCV and tomorrow?
Maria BUTI (Barcelona, Spain)

18:45 Hepatitis Delta: current knowledge and management of patients
Tarik ASSELAH (Paris, France)

19:00 End of the symposium

CIS Auditorium

12:45 SYMPOSIUM NOVO NORDISK
13:45 Preparing for multidisciplinary MASH management: what is your role?



Chairs: Michael RODEN (Dusseldorf, Germany)

Objective: To discuss the barriers to and approaches for implementing effective multidisciplinary management of MASH in clinical practice

12:45 Welcome and introduction
Michael RODEN (Dusseldorf, Germany)

12:55 Barrier 1: Early screening/evaluation
Cyrielle CAUSSY (Lyon, France), Jérôme BOURSIER (Angers, France)

13:10 Barrier 2: Timely referral
Cyrielle CAUSSY (Lyon, France), Jérôme BOURSIER (Angers, France)

13:25 Barrier 3: Optimising cardiometabolic risk management
Cyrielle CAUSSY (Lyon, France), Jérôme BOURSIER (Angers, France)

13:40 Summary and conclusion

Congress center, Room 1

12:45 WORKSHOP ROCHE
13:15 From randomized trials to real-world data (RWD): complementary approaches



Chairs: Marie LEQUOY, Pierre NAHON (France)

12:45 Illustration based on clinical cases
Marie LEQUOY (Paris, France)

12:55 How can RWD impact clinical practice?
Pierre NAHON (Bobigny, France)

13:10 Questions / Debates

14:00 R&D SESSION 2:
14:45 The drug pipelines presented by Companies

Chairs: Raymond SCHINAZI (USA), Geoffrey DUSHEIKO (UK)

14:00 NOVO NORDISK
Novo Nordisk's commitment in Liver Disease
Dmitry ESTULIN (Senior Medical Director, Novo Nordisk)

14:15 AKERO
Efruxifermin for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Vlad RATZIU (Hospital Pitié-Salpêtrière, Paris, France)

14:30 MADRIGAL PHARMACEUTICALS
Overview and Update on the MAESTRO Development Program
Peter RYDQVIST (European Medical Director, Madrigal Pharmaceuticals)

SILVER PARTNERS



BRONZE PARTNERS



PARTNERS

